CEFODIZIME (THR-221) IN OBSTETRICS AND GYNECOLOGY
We performed a basic and clinical study on cefodizime (THR-221), an injectable cephem, to evaluate its usefulness in obstetric and gynecological infections. Favorable distribution to the uterus and adnexa was shown after administration of the drug at 1g, and the levels in these tissues were enough t...
Saved in:
Published in | CHEMOTHERAPY Vol. 36; no. Supplement5; pp. 927 - 931 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | Japanese |
Published |
Japanese Society of Chemotherapy
1988
|
Online Access | Get full text |
Cover
Loading…
Summary: | We performed a basic and clinical study on cefodizime (THR-221), an injectable cephem, to evaluate its usefulness in obstetric and gynecological infections. Favorable distribution to the uterus and adnexa was shown after administration of the drug at 1g, and the levels in these tissues were enough to cover main pathogens in the treatment of various obstetric and gynecological infections. Two grams per i. v. injection (or drip infusion) was given to a total of 14 patients with pelvic infections (intrauterine infection, pyometra, adnexitis, etc.) and puerperal endometritis, and the efficacy rate was 85.7%(12 patients). Bacteriologically, isolates included various anaerobes, Streptococcus, aerobic Gram-negative bacilli, etc. Three strains were eliminated and 2 strains (E. cloacae) replaced. No notable adverse reactions occurred and no abnormal laboratory finding were detected. |
---|---|
ISSN: | 0009-3165 1884-5894 |
DOI: | 10.11250/chemotherapy1953.36.Supplement5_927 |